# EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

> **NCT03497689** · PHASE4 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

## Key facts

- **NCT ID:** NCT03497689
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03497689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03497689, "EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03497689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*